ES2569354T3 - Forma farmacéutica multiparticular, que contiene productos activos de ácido nucleico de formulación mucoadhesiva, así como un procedimiento para la obtención de la forma farmacéutica - Google Patents
Forma farmacéutica multiparticular, que contiene productos activos de ácido nucleico de formulación mucoadhesiva, así como un procedimiento para la obtención de la forma farmacéutica Download PDFInfo
- Publication number
- ES2569354T3 ES2569354T3 ES05807707.4T ES05807707T ES2569354T3 ES 2569354 T3 ES2569354 T3 ES 2569354T3 ES 05807707 T ES05807707 T ES 05807707T ES 2569354 T3 ES2569354 T3 ES 2569354T3
- Authority
- ES
- Spain
- Prior art keywords
- mucoadhesive
- polymer
- range
- multiparticular
- pharmaceutical form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Forma farmacéutica oral multiparticular, que contiene aglomerados en bolas con un diámetro medio en el intervalo de 50 a 2500 μm, que está constituida esencialmente por a) una capa matriz interna que contiene nanopartículas que comprenden un producto activo de ácido nucleico, y están alojados una matriz constituida por un polímero con acción mucoadhesiva, pudiendo contener la matriz opcionalmente otras substancias auxiliares habituales desde el punto de vista farmacéutico, b) un revestimiento externo peliculado, constituido esencialmente por un polímero o copolímero aniónico, que puede ser formulado opcionalmente con substancias auxiliares habituales desde el punto de vista farmacéutico, en especial plastificantes, caracterizada por que la forma farmacológica multiparticular es formulada de modo que los aglomerados en bolas contenidos se liberan en el intervalo de pH del estómago, el revestimiento externo, mediante la selección de polímero o copolímero aniónico, o bien su formulación con substancias auxiliares y su grosor de capa, se ajusta de modo que se disuelve en intervalos de pH de 4,0 a 8,0 en el intestino en el intervalo de 15 a 60 min, de modo que la capa matriz que contiene producto activo, mucoadhesiva, se libera, se puede unir a la mucosa intestinal y liberar el producto activo en la misma, seleccionándose el polímero con acción mucoadhesiva de modo que, en un intervalo de +/- 0,5 unidades de pH, referido al valor de pH al que el revestimiento externo empieza a disolverse, presenta una acción mucoadhesiva de al menos ηb >=150 a 1000 mPa.s y una absorción de agua de un 10 a un 750 % en 15 minutos, y la fracción de producto activo de las nanopartículas en la capa matriz asciende como máximo a un 40 % en peso del contenido en el polímero con acción mucoadhesiva.
Description
farmacéutica
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004059792 | 2004-12-10 | ||
DE102004059792A DE102004059792A1 (de) | 2004-12-10 | 2004-12-10 | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
PCT/EP2005/011864 WO2006061069A1 (de) | 2004-12-10 | 2005-11-05 | Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte nukleinsäure-wirkstoffe, sowie ein verfahren zur herstellung der arzneiform |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2569354T3 true ES2569354T3 (es) | 2016-05-10 |
Family
ID=35709359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES05807707.4T Active ES2569354T3 (es) | 2004-12-10 | 2005-11-05 | Forma farmacéutica multiparticular, que contiene productos activos de ácido nucleico de formulación mucoadhesiva, así como un procedimiento para la obtención de la forma farmacéutica |
Country Status (17)
Country | Link |
---|---|
US (1) | US8568778B2 (es) |
EP (1) | EP1824457B1 (es) |
JP (1) | JP5578764B2 (es) |
KR (1) | KR101319773B1 (es) |
CN (1) | CN101060835B (es) |
BR (1) | BRPI0515815B8 (es) |
CA (1) | CA2586597C (es) |
DE (1) | DE102004059792A1 (es) |
ES (1) | ES2569354T3 (es) |
HK (1) | HK1110205A1 (es) |
HU (1) | HUE028793T2 (es) |
IL (1) | IL183753A (es) |
MX (1) | MX2007006343A (es) |
PL (1) | PL1824457T3 (es) |
SI (1) | SI1824457T1 (es) |
TW (1) | TW200635617A (es) |
WO (1) | WO2006061069A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
RU2009102262A (ru) * | 2006-06-26 | 2010-08-10 | Мьючуал Фармасьютикал Компани, Инк. (Us) | Композиции активного агента, способы их получения и способы применения |
CN101801358A (zh) * | 2007-07-16 | 2010-08-11 | 东北大学 | 治疗性稳定的纳米颗粒 |
DE102008048729A1 (de) * | 2008-09-24 | 2010-03-25 | Add Technologies Ltd Advanced Drug Delivery | Multipartikuläre Tabletten und Verfahren zur deren Herstellung |
EP2521570A4 (en) * | 2009-12-29 | 2015-05-13 | Impax Laboratories Inc | SOLID ORAL DOSAGE FORMS WITH GASTRORETTENTION EFFECT, COMPRISING AN INFLATABLE HYDROPHILIC POLYMER |
AU2010346995B2 (en) | 2010-02-25 | 2014-12-04 | Evonik Operations Gmbh | Pharmaceutical or neutraceutical formulation |
CN102250878B (zh) * | 2011-06-03 | 2013-01-23 | 吉林大学 | 一种基于固相介质表面电荷的反转提取dna的方法 |
US9107851B2 (en) * | 2012-10-15 | 2015-08-18 | New Jersey Institute Of Technology | Solventless mixing process for coating pharmaceutical ingredients |
JP6912876B2 (ja) * | 2016-10-06 | 2021-08-04 | 三洋化成工業株式会社 | アクリル系医薬固形製剤用添加剤 |
CN110603057A (zh) * | 2017-03-17 | 2019-12-20 | 俄亥俄州创新基金会 | 用于递送化学预防剂的纳米颗粒 |
BR112020023983A2 (pt) | 2018-05-24 | 2021-02-23 | Celanese Eva Performance Polymers Llc | dispositivo implantável para liberação prolongada de um composto de fármaco macromolecular |
WO2019226519A1 (en) | 2018-05-24 | 2019-11-28 | Celanese EVA Performance Polymers Corporation | Implantable device for sustained release of a macromolecular drug compound |
DE102020002360A1 (de) * | 2020-04-18 | 2021-10-21 | Friedrich-Schiller-Universität Jena | Nanopartikel enthaltend Komplexe aus Nukleinsäuren und kationischen Copolymeren, Verfahren zu deren Herstellung und deren Verwendung zum Gentransfer in Zellen |
WO2023249087A1 (ja) * | 2022-06-24 | 2023-12-28 | 三生医薬株式会社 | 医薬組成物およびその製造方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW209174B (es) | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
ES2242198T3 (es) * | 1995-10-25 | 2005-11-01 | Octoplus B.V. | Poliacrilatos y poli(alquil) acrilatos cationicos o las correspondientes acrilamidas para utilizar en sistemas de transfeccion sinteticos. |
GB9700624D0 (en) * | 1997-01-14 | 1997-03-05 | Danbiosyst Uk | Drug delivery composition |
US6730735B2 (en) * | 1997-07-03 | 2004-05-04 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited | Conjugate of polyethylene glycol and chitosan |
EP1203590B1 (en) * | 1999-08-09 | 2007-07-04 | Dainippon Sumitomo Pharma Co., Ltd. | Solid preparations containing chitosan powder and process for producing the same |
US7803392B2 (en) * | 2000-12-27 | 2010-09-28 | University Of Kentucky Research Foundation | pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules |
WO2003007913A2 (en) * | 2001-07-20 | 2003-01-30 | Samir Mitragotri | Method for oral drug delivery |
US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
DE10332160A1 (de) | 2003-07-15 | 2005-02-03 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
DE10353196A1 (de) * | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
DE10353186A1 (de) * | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
US20040224019A1 (en) * | 2004-03-03 | 2004-11-11 | Adi Shefer | Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs |
DE102004036437A1 (de) * | 2004-07-27 | 2006-03-23 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform für wenig lösliche Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
DE102006035549A1 (de) * | 2006-07-27 | 2008-01-31 | Evonik Röhm Gmbh | Arzneiform mit mindestens zweischichtiger Trennschicht |
-
2004
- 2004-12-10 DE DE102004059792A patent/DE102004059792A1/de not_active Withdrawn
-
2005
- 2005-11-05 HU HUE05807707A patent/HUE028793T2/hu unknown
- 2005-11-05 US US11/721,399 patent/US8568778B2/en active Active
- 2005-11-05 CA CA2586597A patent/CA2586597C/en active Active
- 2005-11-05 SI SI200532058A patent/SI1824457T1/sl unknown
- 2005-11-05 CN CN200580037293XA patent/CN101060835B/zh active Active
- 2005-11-05 JP JP2007544750A patent/JP5578764B2/ja active Active
- 2005-11-05 MX MX2007006343A patent/MX2007006343A/es unknown
- 2005-11-05 WO PCT/EP2005/011864 patent/WO2006061069A1/de active Application Filing
- 2005-11-05 KR KR1020077012902A patent/KR101319773B1/ko active IP Right Grant
- 2005-11-05 EP EP05807707.4A patent/EP1824457B1/de active Active
- 2005-11-05 BR BRPI0515815A patent/BRPI0515815B8/pt active IP Right Grant
- 2005-11-05 PL PL05807707T patent/PL1824457T3/pl unknown
- 2005-11-05 ES ES05807707.4T patent/ES2569354T3/es active Active
- 2005-11-16 TW TW094140339A patent/TW200635617A/zh unknown
-
2007
- 2007-06-07 IL IL183753A patent/IL183753A/en active IP Right Grant
-
2008
- 2008-01-21 HK HK08100739.8A patent/HK1110205A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DE102004059792A1 (de) | 2006-06-14 |
BRPI0515815B8 (pt) | 2021-05-25 |
IL183753A0 (en) | 2007-09-20 |
CN101060835B (zh) | 2013-01-02 |
KR20070085894A (ko) | 2007-08-27 |
BRPI0515815A (pt) | 2008-08-05 |
US8568778B2 (en) | 2013-10-29 |
CA2586597C (en) | 2013-09-10 |
JP5578764B2 (ja) | 2014-08-27 |
IL183753A (en) | 2016-12-29 |
PL1824457T3 (pl) | 2016-07-29 |
MX2007006343A (es) | 2007-07-04 |
EP1824457B1 (de) | 2016-02-17 |
KR101319773B1 (ko) | 2013-10-17 |
WO2006061069A1 (de) | 2006-06-15 |
CA2586597A1 (en) | 2006-06-15 |
BRPI0515815B1 (pt) | 2019-02-05 |
SI1824457T1 (sl) | 2016-06-30 |
HUE028793T2 (hu) | 2017-01-30 |
CN101060835A (zh) | 2007-10-24 |
US20090280183A1 (en) | 2009-11-12 |
HK1110205A1 (en) | 2008-07-11 |
JP2008522989A (ja) | 2008-07-03 |
EP1824457A1 (de) | 2007-08-29 |
TW200635617A (en) | 2006-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2569354T3 (es) | Forma farmacéutica multiparticular, que contiene productos activos de ácido nucleico de formulación mucoadhesiva, así como un procedimiento para la obtención de la forma farmacéutica | |
ECSP088240A (es) | Composición de trazodona para administración una vez por día | |
EP2011487A3 (en) | Pharmaceutical compositions for gastroinetestinal drug delivery | |
WO2008067127A3 (en) | Water insoluble polymer matrix for drug delivery | |
CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
ATE493973T1 (de) | Irbesartan enthaltende pharmazeutische zusammensetzung | |
ES2572157T3 (es) | Composiciones en forma de partículas para la administración de fármacos poco solubles | |
NZ601200A (en) | Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) | |
CL2008001966A1 (es) | Composicion de disolucion oral que comprende lamotrigina,en forma de particulas con lamotrigina recubiertas con una capa para enmascarar el sabor y granulos que comprenden un desinfectante y un alcohol de azucar y/o un hidrato de carbono; metodo de preparacion;uso para tratar trastornos del humor y prevencion de ataques. | |
WO2009041651A1 (ja) | 速崩壊性固形製剤 | |
EA200900087A1 (ru) | Применение гидрофильной матрицы, содержащей производное полиакриловой кислоты, простой эфир целлюлозы и дезинтегрирующий агент, в производстве медикаментов для лечения заболеваний женских гениталий | |
CL2007002866A1 (es) | Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m | |
WO2008073282A3 (en) | Ph sensitive matrix formulation | |
AR062167A1 (es) | Sistema de administracion gastrorretentivo | |
WO2009048945A8 (en) | Rapid mucosal gel or film insulin compositions | |
CL2007001724A1 (es) | Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1 | |
MX2009004439A (es) | Composicion de ibuprofeno. | |
AR061790A1 (es) | Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento | |
PE20061015A1 (es) | Formas farmaceuticas con propiedades farmacocineticas mejoradas | |
AR086249A1 (es) | Composiciones de tabletas de disolucion rapida de administracion vaginal | |
WO2008084504A3 (en) | Pharmaceutical compositions of angiotensin ii receptor blockers | |
CL2007002921A1 (es) | Forma solida de dosificacion farmaceutica de administracion oral, que comprende una forma cristalina o amorfa de un compuesto microincluido en un polimero ionico insoluble en agua en proporcion 5:1 a 1:5; y metodo de preparacion. | |
JP5096921B2 (ja) | 経粘膜搬送デバイス | |
JP2012517449A5 (es) | ||
ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan |